.Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EE01_Latanoprost.Latanoprost .Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EE01_Latanoprost.Latanoprost| name: | Latanoprost |
| ATC code: | S01EE01 | route: | ophthalmic |
| n-compartments | 1 |
Latanoprost is a prostaglandin F2α analogue used primarily for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is an ophthalmic solution administered as one drop in the affected eye(s) once daily. It is widely approved and used in clinical practice.
Pharmacokinetic parameters reported in healthy adult volunteers after topical ocular administration.
Digiuni, M, et al., & Rossetti, L (2013). An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension. Journal of glaucoma 22(9) 707–712. DOI:10.1097/IJG.0b013e318259b47c PUBMED:https://pubmed.ncbi.nlm.nih.gov/22595934
Lallemand, F, et al., & Garrigue, JS (2012). Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. Journal of drug delivery 2012 604204–None. DOI:10.1155/2012/604204 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22506123
Hariharan, S, et al., & Mitra, AK (2009). Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 25(6) 487–498. DOI:10.1089/jop.2009.0049 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20028257